A novel membrane-based anti-diabetic action of atorvastatin

We recently found that chromium picolinate (CrPic), a nutritional supplement thought to improve insulin sensitivity in individuals with impaired glucose tolerance, enhances insulin action by lowering plasma membrane (PM) cholesterol. Recent in vivo studies suggest that cholesterol-lowering statin dr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biochemical and biophysical research communications 2008-08, Vol.372 (4), p.639-643
Hauptverfasser:	Horvath, Emily M, Tackett, Lixuan, Elmendorf, Jeffrey S
Format:	Artikel
Sprache:	eng
Schlagworte:	3T3-L1 Cells Adipocytes - drug effects Adipocytes - metabolism Animals Atorvastatin Calcium Cell Membrane - drug effects Cell Membrane - metabolism Cholesterol - metabolism Heptanoic Acids - pharmacology Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology Hypoglycemic Agents - pharmacology Insulin - pharmacology Insulin Resistance Mice Picolinic Acids - pharmacology Pyrroles - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We recently found that chromium picolinate (CrPic), a nutritional supplement thought to improve insulin sensitivity in individuals with impaired glucose tolerance, enhances insulin action by lowering plasma membrane (PM) cholesterol. Recent in vivo studies suggest that cholesterol-lowering statin drugs benefit insulin sensitivity in insulin-resistant patients, yet a mechanism is unknown. We report here that atorvastatin (ATV) diminished PM cholesterol by 22% (P
ISSN:	0006-291X 1090-2104
DOI:	10.1016/j.bbrc.2008.05.095